Effect of Alemtuzumab Infusions on Vital Signs: A Prospective Observational Study in Patients with Relapsing-Remitting Multiple Sclerosis

Alemtuzumab efficacy and safety were established in phase 3 randomized trials. We characterize vital signs during and after the first alemtuzumab infusion course. Patients with relapsing-remitting multiple sclerosis commercially prescribed alemtuzumab 12 mg/day on 5 consecutive days (initial course)...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	International journal of MS care 2020-03, Vol.22 (2), p.53-59
Hauptverfasser:	Chinea, Angel, Honeycutt, William David, Miller, Tamara, Graves, Donna, Jacobs, Alan, Wu, Junlong, LaGanke, Christopher C
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!